Royalty Pharma plc has entered a $100 million agreement with Zealand Pharma for economic rights tied to rusfertide (PTG-300), a drug candidate for polycythemia vera. The deal gives Royalty Pharma a 1% royalty on potential future global net sales as well as rights linked to regulatory and commercial milestones, while Zealand Pharma will receive $50 million at closing and another $50 million on the first anniversary of the agreement. For annual global net sales above $1.5 billion, Zealand will keep a 0.25% royalty and Royalty Pharma will receive 0.75%. The U.S. FDA (U.S. drug regulator) has set a Prescription Drug User Fee Act (PDUFA) goal date for rusfertide's New Drug Application in the third quarter of 2026, and Takeda Pharmaceutical Co Ltd is responsible for global commercialization. The transaction adds another healthcare royalty asset to Royalty Pharma's portfolio following its July deal to buy part of Neurimmune's royalty interest in AstraZeneca plc's cliramitug for up to $425 million.